Preoperative Gamma-Glutamyltransferase Is Associated with Cancer-Specific Survival and Recurrence-Free Survival of Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus
Table 2
Univariate analysis of various variables for predicting CSS and RFS.
Variables
CSS
RFS
HR (95% CI)
p value
HR (95% CI)
p value
Age, year (≥60 versus <60)
1.315 (0.731–2.367)
0.361
1.204 (0.743–1.951)
0.451
BMI, kg/m2 (<25 versus ≥25)
1.769 (0.853–3.669)
0.125
2.387 (0.733–2.260)
0.379
Gender (female versus male)
1.457 (0.799–2.659)
0.220
1.042 (0.611–1.777)
0.879
Symptom presentation (yes versus no)
2.430 (1.172–5.036)
0.017
1.546 (0.899–2.657)
0.115
ASA (3 + 4 versus 1 + 2)
1.488 (0.691–3.203)
0.310
1.674 (0.892–3.140)
0.109
Tumor laterality (right versus left)
1.189 (0.890–1.588)
0.241
1.052 (0.826–1.339)
0.682
Tumor thrombus level (IVC versus RV)
1.531 (1.130–2.074)
0.006
1.345 (1.055–1.715)
0.017
Maximum tumor width, cm (≥10 versus <10)
1.392 (1.041–1.860)
0.026
1.258 (0.987–1.603)
0.064
Pathological stage (T3b-4 versus T3a)
2.926 (1.539–5.563)
<0.001
2.170 (1.315–3.578)
0.002
Lymph node invasion (N+ versus N0/Nx)
1.885 (0.909–3.909)
0.088
1.802 (0.963–3.370)
0.065
Fuhrman grade (G3 + G4 versus G1 + G2)
2.306 (1.275–4.173)
0.006
2.024 (1.247–3.285)
0.004
Histological subtype (clear-cell versus non-clear-cell)
1.038 (0.652–1.653)
0.875
1.057 (0.714–1.565)
0.781
Sarcomatoid feature (yes versus no)
1.740 (0.901–3.364)
0.099
1.692 (0.976–2.936)
0.061
GGT, IU/L (≥37.5 versus <37.5)
2.992 (1.668–5.368)
<0.001
2.587 (1.580–4.236)
<0.001
CSS: cancer-specific survival; RFS: recurrence-free survival; HR: hazard ratio; BMI: body mass index; ASA: American Society of Anesthesiologists; IVC: inferior vena cava; RV: renal vein; GGT: gamma-glutamyltransferase.
